CN116600830A - 缀合的tlr7和nod2激动剂 - Google Patents

缀合的tlr7和nod2激动剂 Download PDF

Info

Publication number
CN116600830A
CN116600830A CN202180085916.XA CN202180085916A CN116600830A CN 116600830 A CN116600830 A CN 116600830A CN 202180085916 A CN202180085916 A CN 202180085916A CN 116600830 A CN116600830 A CN 116600830A
Authority
CN
China
Prior art keywords
alkyl
compound
alkoxy
cycloalkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180085916.XA
Other languages
English (en)
Chinese (zh)
Inventor
齐加·亚科平
沙莫·古泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Univerza Ljubljana v Fakulteta za Farmazijo
Original Assignee
Univerza Ljubljana v Fakulteta za Farmazijo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerza Ljubljana v Fakulteta za Farmazijo filed Critical Univerza Ljubljana v Fakulteta za Farmazijo
Publication of CN116600830A publication Critical patent/CN116600830A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180085916.XA 2020-10-21 2021-10-20 缀合的tlr7和nod2激动剂 Pending CN116600830A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU102145 2020-10-21
LULU102145 2020-10-21
PCT/EP2021/079141 WO2022084417A1 (en) 2020-10-21 2021-10-20 Conjugated tlr7 and nod2 agonists

Publications (1)

Publication Number Publication Date
CN116600830A true CN116600830A (zh) 2023-08-15

Family

ID=74175904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180085916.XA Pending CN116600830A (zh) 2020-10-21 2021-10-20 缀合的tlr7和nod2激动剂

Country Status (7)

Country Link
US (1) US20230382886A1 (https=)
EP (1) EP4232094A1 (https=)
JP (1) JP2023546205A (https=)
CN (1) CN116600830A (https=)
AU (1) AU2021363606A1 (https=)
CA (1) CA3196221A1 (https=)
WO (1) WO2022084417A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy
WO2025040743A1 (en) * 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166681A1 (en) * 2013-08-15 2016-06-16 Sunil Abraham David Toll-like receptor agonists
US20180065938A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
CN101790380B (zh) * 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
WO2019197598A1 (en) 2018-04-13 2019-10-17 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166681A1 (en) * 2013-08-15 2016-06-16 Sunil Abraham David Toll-like receptor agonists
US20180065938A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALICE GUTJAHR ET AL.: "New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses", 《EBIOMEDICINE. 》, vol. 58, 30 July 2020 (2020-07-30), pages 5 *
GEOFFROY P.P. GENTIAL: "Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 29, no. 11, 1 June 2019 (2019-06-01), pages 1 *
MARTINA GOBEC: "Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties", 《J MED CHEM.》, vol. 61, no. 7, 12 April 2018 (2018-04-12), pages 9 *

Also Published As

Publication number Publication date
AU2021363606A9 (en) 2025-01-09
AU2021363606A1 (en) 2023-06-01
US20230382886A1 (en) 2023-11-30
WO2022084417A1 (en) 2022-04-28
CA3196221A1 (en) 2022-04-28
JP2023546205A (ja) 2023-11-01
EP4232094A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CN108794422B (zh) 作为pd-l1抑制剂的杂环类化合物
CN108290845B (zh) 嘧啶化合物
ES2804101T3 (es) Compuestos de 4-amino-imidazoquinolina
ES2577514T3 (es) Antagonistas de TLR
JP5357022B2 (ja) 多機能生物活性化合物
US10640520B2 (en) Boronic acid derivatives
CN113150016A (zh) 用于抑制精氨酸酶活性的组合物和方法
CN116600830A (zh) 缀合的tlr7和nod2激动剂
CN119301105A (zh) 用于治疗癌症的基于硫链丝菌肽的化合物及其制备
EP3389643B1 (en) Novel muramyl peptide derivative compound, synthesis and uses thereof
Yang et al. Next-generation diprovocims with potent human and murine TLR1/TLR2 agonist activity that activate the innate and adaptive immune response
CA3026178A1 (en) Diprovocims: a new and potent class of tlr agonists
AU2002312656B8 (en) Peptoid compounds
US10927147B2 (en) Muramyl peptide derivative compound, synthesis and uses thereof
WO2025093657A1 (en) Conjugated tlr7 and tlr4 agonists
WO2025040743A1 (en) Conjugated tlr7 and rig-i agonists
CN112512590A (zh) Tlr7肽缀合物
CN105899234A (zh) Dupa-茚并异喹啉缀合物
US20250367166A1 (en) Next generation diprovocims that activate the innate and adaptive immune response
WO2012169785A9 (en) Symmetrically structured quinazoline derivatives
Wu Modulators of Toll-like Receptors-4 and-2
WO2024112932A1 (en) Immunomodulators and immunomodulator conjugates
HK1126114A (en) Tlr agonists
JPH0912523A (ja) ヘプタン酸誘導体およびその医薬用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination